All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Product Name: BioLexa
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
Following the successful completion of the Phase 1b trial, the Company intends to conduct a Phase 2 trial with adult and adolescent patients to continue clinical investigation of the efficacy of BioLexa Lotion for treatment of mild to moderate atopic dermatitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP1815
Therapeutic Area: Dermatology Product Name: EDP1815
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
Treatment with EDP1815 demonstrates statistically and clinically significant improvement in mean EASI and IGA* BSA scores. EDP1815 first-ever candidate targeting SINTAX™ to show clinical activity in Th1, Th2, and Th17-mediated inflammation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cannabinol
Therapeutic Area: Dermatology Product Name: INM-755
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 16, 2020
Details:
InMed intends to use the net proceeds from the offering for funding preclinical and clinical development of its cannabinoid drug candidates INM-755 (dermatology) and INM-088 (ocular diseases), advancing its IntegraSynTM manufacturing platform, and for working capital purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GLPG3667
Therapeutic Area: Dermatology Product Name: GLPG3667
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
This Phase 1b trial is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of GLPG3667.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OLX10010
Therapeutic Area: Dermatology Product Name: OLX10010
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2020
Details:
U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to evaluate the efficacy of OLX10010 as an adjunct therapy to reduce the recurrence of hypertrophic scars after scar revision surgery.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ASLAN004
Therapeutic Area: Dermatology Product Name: ASLAN004
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
ASLAN004 was found to be well tolerated at 400mg and the DMC has recommended that the multiple ascending dose (MAD) clinical study continue as planned.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 14, 2020
Details:
The funds support the acceleration of Nimbus’ Phase 1 allosteric tyrosine kinase 2 inhibitor into Phase 2 early next year, its hematopoietic progenitor kinase 1 inhibitor into the clinic next year, as well as the advancement of its preclinical portfolio of new medicines.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDP1815
Therapeutic Area: Dermatology Product Name: EDP1815
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
EDP1815-101 is a double-blind, placebo-controlled Phase 1b trial designed to evaluate the safety and tolerability of EDP1815 in healthy volunteers and patients with psoriasis or atopic dermatitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KB301
Therapeutic Area: Dermatology Product Name: KB301
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The Phase 1 PEARL-1 clinical study will evaluate KB301 in acne scars and fine wrinkles is currently enrolling.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HST-001
Therapeutic Area: Dermatology Product Name: HST-001
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
This blinded, randomized, placebo controlled, single site study has enrolled 36 subjects with male pattern hair loss using a 2:1 randomization of HST-001 to placebo.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
